68240-86-8

Upstream product

• 3457-46-3 4,4'-dichlorobenzil 
• 4254-20-0 4,4'-dichlorobenzoin 
• 68-12-2 N,N-dimethyl-formamide 
• 2213-43-6 1-Aminopiperidine 
• 489447-14-5 4,5-di-(4-chlorophenyl)-1-methylimidazole-2-carboxylic acid 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 13733-23-8 N,N'-carbonylbis(4-chlorobenzamide) 
• 489447-26-9 4,5-di-(4-chlorophenyl)-1-(2-(trimethylsilyl)ethoxymethyl)imidazole 
• 74491-36-4 4,5-bis-4-chlorophenyl-1-methylimidazole 
• 1309776-57-5 C₂₂H₁₄Cl₂N₂O 
• 1309776-59-7 C₂₂H₁₃Cl₃N₂O 
• 1309776-58-6 2-(4-methoxybenzoyl)-4,5-di(4-chlorophenyl)imidazole 
• 489447-31-6 benzyl 4,5-di-(4-chlorophenyl)-1-(2-(trimethylsilyl)ethoxymethyl)imidazole-2-carboxylate 
• 849722-44-7 4,5-bis-(4-chloro-phenyl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid 
• 489447-10-1 N-(piperidin-1-yl)-4,5-di-(4-chlorophenyl)-1-methylimidazole-2-carboxamide 

Relevant academic research and scientific papers

Synthesis, cytotoxic and antibacterial studies of p-benzyl-substituted NHC-silver(I) acetate compounds derived from 4,5-di-p-diisopropylphenyl- or 4,5-di-p-chlorophenyl-1H-imidazole

4,5-Di(p-isopropylphenyl)-1H-imidazole (2a) and 4,5-di(p-chlorophenyl)-1H- imidazole (2b) were prepared from the appropriately substituted benzoin precursors and then reacted with five p-substituted benzyl halide derivatives through N-dibenzylation to the

Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists

Structure-activity relationship studies directed toward the optimization of 4,5-diarylimidazole-2-carboxamide analogs as human CB1 receptor inverse agonists resulted in the discovery of the two amide derivatives 24a and b (hCB1 IC50 = 6.1 and 4

Substituted imidazoles as cannabinoid receptor modulators

The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Novel compounds of structural formula (I) are also claimed.

Photoreactions of 4,5-diarylimidazoles: Singlet oxygenation and cyclodehydrogenation

4,5-Diarylimidazoles (1) undergo singlet oxygenation and cleavage to give N,N'-diaroylureas (2) on irradiation in alcoholic solutions in the presence of methylene blue as sensitizer. 5-Methoxy-4,5-diphenylimidazolin-2-one (5) and 4,5-dimethoxy-4,5-diphenylimidazolidin-2-one (6) have been reported as the principal products in the dye-sensitized irradiation of 4,5-diphenylimidazole in methanol.The formation of diaroylureas appears to proceed through the intermediacy of the corresponding imidazolin-2-one.A mechanistic pathway for the photochemical dye-sensitized oxygenation of the imidazoles is suggested.The photochemical cyclodehydrogenation reaction of the stilbene system present in 4,5-diarylimidazoles has also been carried out.